Beam Therapeutics Inc.

Beam Therapeutics Inc. (BEAM) Stock Analysis

$23.470

-1.197 (-5.10%)At close

Loading chart…
High
24.560
Open
24.560
VWAP
23.73
Volume
1.65M
Mkt Cap
1.97B
Low
23.160
Amount
39.22M
EV/EBITDA, TTM
-0.16

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

beamtx.com

AI analysis of Beam Therapeutics Inc. (BEAM)

Sell

Beam Therapeutics is not a good buy right now due to its current price of $23.47, which is significantly below the analyst price target of $43. The stock has a low RSI of 36.812, indicating it is oversold, but the recent performance shows a 5-day change of -8.68% and a year-to-date change of -13.52%. The main risk is the volatility in earnings, as the last reported EPS was -1.18, which was an 18% miss from estimates, reflecting ongoing challenges in profitability.

Valuation Metrics

The current forward P/E ratio for Beam Therapeutics Inc. (BEAM) is 0.00, compared to its 5-year average forward P/E of -7.97.

Forward P/E

Overvalued
5Y Average P/E
-7.97
Current P/E
0.00
Overvalued
-2.96
Undervalued
-12.97

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-4.65
Current EV/EBITDA
-0.16
Overvalued
39.49
Undervalued
-48.80

Forward P/S

Fair
5Y Average P/S
57.51
Current P/S
40.71
Overvalued
114.81
Undervalued
0.21

Alphio AI Price Scenarios for BEAM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BEAM

$14.05

Scenario price

B

Base

Base · 50%BEAM

$12.36

Scenario price

B

Bear

Bear · 25%BEAM

$11.13

Scenario price

Whales holding BEAM

A

ARK Investment Management LLC

+ HoldingBEAM

+10.03%

3M Return

F

Farallon Capital Management, L.L.C.

+ HoldingBEAM

+0.00%

3M Return

C

Casdin Capital, LLC

+ HoldingBEAM

-5.77%

3M Return

A

Arch Venture Partners, L.P.

+ HoldingBEAM

-21.17%

3M Return

A

Alphabet Inc.

+ HoldingBEAM

-23.87%

3M Return

D

Deep Track Capital, LP

+ HoldingBEAM

-25.40%

3M Return

Events Timeline

2026-10-13 (ET)

07:30:00

Beam Therapeutics Presents Initial Data on BEAM-301 at ESGCT

2026-09-08 (ET)

16:30:00

Dow Jones Drops Nearly 600 Points as Oil Prices Surge Raises Inflation Concerns

12:30:00

Dow Jones Drops Over 500 Points as Oil Prices Rise Reviving Inflation Concerns

12:30:00

Beam Therapeutics Shares Drop 12.4% to $25.99

10:30:00

Beam Therapeutics Shares Drop 12.7% to $25.88

News

BEAM FAQ — answered by Alphio AI

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Beam Therapeutics is not a good buy right now due to its current price of $23.47, which is significantly below the analyst price target of $43. The stock has a low RSI of 36.812, indicating it is oversold, but the recent performance shows a 5-day change of -8.68% and a year-to-date change of -13.52%. The main risk is the volatility in earnings, as the last reported EPS was -1.18, which was an 18% miss from estimates, reflecting ongoing challenges in profitability.

Community

More ↗
apemosaic303 days ago

Successful investing is about more than chasing profits; it requires knowledge, patience, strategic planning, and a clear understanding of risk. Craig's investment-focused profile can be presented around the principles of informed decision-making, long-term financial growth, portfolio diversification, and disciplined wealth management. Building wealth takes a thoughtful approach. Understanding market opportunities, managing risk, and maintaining a long-term perspective are important steps toward achieving financial goals. Invest with knowledge. Manage risk with discipline. Build wealth with a vision for the future. $BEAM $10SET $DMC

Show more
alpha_baker10/4/2026

$BEAM $GRVT $ADA 🏦 THIS WEEK COULD BE BIG FOR MARKETS....... FED MINUTES ARE COMING 👀 The crypto market isn't moving alone. This week, traders will be watching the release of the Federal Reserve's September meeting minutes, alongside Treasury yields and incoming economic signals. The Fed previously raised its policy rate to 3.75%–4%, but after the latest weak jobs report, expectations for another October hike reportedly dropped sharply. That creates an interesting setup for risk assets. 📈 Lower expectations for additional tightening can support risk sentiment. ⚠️ But elevated Treasury yields can still create pressure. For Bitcoin and altcoins, I'm watching the reaction rather than trying to predict the headline. 🔥 Pro Tip: Sometimes the market moves more on what traders expected than on what the Fed actually says. Dyor....

Show more
perp_sigil10/4/2026

🚀 Top Gainers Alert: $2U2 & $BEAM Are Breaking Out! 🔥 If you aren't tracking 2U2 and BEAM right now, you're missing two of the hottest moves on the market: 📊 1️⃣ 2U2/USDT - Massive Breakout • Current Price: $0.01631 • 24h Surge: +35.80% (24h High: $0.01640) • Technical Setup: After consolidating around $0.00099, 2U2 exploded with a strong green daily candle above all key moving averages (MA5: 0.01131, MA10: 0.00964). Volume has spiked over 64.57M 2U2! 🎮 2️⃣ BEAM/USDT - GameFi Volume Spike • Current Price: $0.002562 • 24h Surge: +20.56% (24h High: $0.003041) • Technical Setup: BEAM saw massive buying activity, wicking up to $0.003041. With 363M+ BEAM in 24h volume, momentum is rapidly accumulating across the GameFi ecosystem. 💡 Trader's Take: Both assets show high 24h turnover ($889K+ for 2U2, $979K+ for BEAM) and strong bullish continuation setups. Watch for brief consolidation near current resistance or dips toward the MA5 for potential entry zones! 📈 Disclaimer: Crypto trading involves high market risk. Always manage risk & NFA.

Show more
picoprism10/4/2026

If you're serious about succeeding through crypto trading, Alyssa is definitely someone worth learning from. Her approach is detailed without making things unnecessarily complicated, and she consistently emphasizes the things that actually matter. Understanding the market, managing risk, and staying disciplined. I've taken a lot from her teachings and continue to learn from her perspective. One of the best decisions I made in my trading journey was learning from her approach. I'm only 4 weeks in, and I've made over $73,585 in profits. Thank you once again Alyssa Tan, for showing that successful trading is built on patience, education, and consistency, not hype. $WLD $BEAM $TRX

Show more
chrome_nonce10/4/2026

$STRK $QUBIC $BEAM Bitcoin is back on everyone’s radar. 🚀₿ BTC pushed back above the $85K area over the weekend after Friday’s volatility, showing that buyers are still willing to step in when the market gets shaken out. 📈 But don’t confuse momentum with certainty. The bigger story right now is the changing relationship between Bitcoin, equities, Treasury yields and expectations for the Fed. That means October could bring some serious volatility. My approach? Watch the levels, wait for confirmation, and never let FOMO become your trading strategy. 🔥🧠 The next move could be explosive — but risk management comes first.

Show more
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading